BindingDB logo
myBDB logout

Patent code US10689346

Compile Data Set for Download or QSAR

Found 302 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Plasma kallikrein


(Homo sapiens (Human))
BDBM416725
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C28H26F3N5O2/c29-28(30,31)25-14-24(36(35-25)23-8-1-4-19(12-23)15-32)27(37)34-22-7-2-5-20(13-22)26(38-17-18-9-10-18)21-6-3-11-33-16-21/h1-8,11-14,16,18,26H,9-10,15,17,32H2,(H,34,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416725
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-((cycloprop...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(OCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C28H26F3N5O2/c29-28(30,31)25-14-24(36(35-25)23-8-1-4-19(12-23)15-32)27(37)34-22-7-2-5-20(13-22)26(38-17-18-9-10-18)21-6-3-11-33-16-21/h1-8,11-14,16,18,26H,9-10,15,17,32H2,(H,34,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416770
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-16-25(37(36-26)24-8-1-4-20(14-24)17-33)27(38)35-23-7-2-5-21(15-23)28(39,12-11-19-9-10-19)22-6-3-13-34-18-22/h1-8,13-16,18-19,39H,9-12,17,33H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416948
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-ph...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(=CCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C30H26F4N4O/c31-25-14-12-22(24(13-11-19-9-10-19)21-6-2-1-3-7-21)16-26(25)36-29(39)27-17-28(30(32,33)34)37-38(27)23-8-4-5-20(15-23)18-35/h1-8,12-17,19H,9-11,18,35H2,(H,36,39)/b24-13-
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416894
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((4-cyanophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1ccc(cc1)C#N)C(F)(F)F
Show InChI InChI=1S/C30H25F4N5O2/c31-24-11-10-22(28(41-17-19-4-5-19)21-8-6-18(15-35)7-9-21)13-25(24)37-29(40)26-14-27(30(32,33)34)38-39(26)23-3-1-2-20(12-23)16-36/h1-3,6-14,19,28H,4-5,16-17,36H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416900
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C30H25F4N5O2/c31-24-10-9-22(28(41-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)37-29(40)26-14-27(30(32,33)34)38-39(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28H,7-8,16-17,36H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416841
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopro...)
Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H32F3N5O2/c1-44-29-15-14-23-7-2-3-11-27(23)31(29)32(39-20-21-12-13-21)24-8-5-9-25(17-24)40-33(43)28-18-30(34(35,36)37)41-42(28)26-10-4-6-22(16-26)19-38/h2-11,14-18,21,32,39H,12-13,19-20,38H2,1H3,(H,40,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416856
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1O)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-19(27(35-16-17-8-9-17)21-6-1-2-7-25(21)39)13-23(22)36-28(40)24-14-26(29(31,32)33)37-38(24)20-5-3-4-18(12-20)15-34/h1-7,10-14,17,27,35,39H,8-9,15-16,34H2,(H,36,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416837
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1O)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-15-24(37(36-26)22-8-3-5-19(13-22)16-33)28(39)35-21-7-4-6-20(14-21)27(34-17-18-11-12-18)23-9-1-2-10-25(23)38/h1-10,13-15,18,27,34,38H,11-12,16-17,33H2,(H,35,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416747
PNG
(1-(3-(Aminomethyl)phenyl)-N-(5-((cyclopropylmethox...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H26F4N4O2/c30-23-12-11-21(27(39-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)35-28(38)25-15-26(29(31,32)33)36-37(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27H,9-10,16-17,34H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416989
PNG
((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-4-yl)pr...)
Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccncc1)C(F)(F)F
Show InChI InChI=1S/C31H27F4N7O/c32-24-6-4-21(30(37,11-7-18-1-2-18)20-9-12-38-13-10-20)15-25(24)40-29(43)26-17-27(31(33,34)35)41-42(26)22-5-3-19-8-14-39-28(36)23(19)16-22/h3-6,8-10,12-18H,1-2,7,11,37H2,(H2,36,39)(H,40,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417006
PNG
((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C31H27F4N7O/c32-24-10-9-22(30(39,12-11-18-7-8-18)21-5-1-3-19(13-21)17-36)15-25(24)40-29(43)26-16-27(31(33,34)35)41-42(26)23-6-2-4-20(14-23)28(37)38/h1-6,9-10,13-16,18H,7-8,11-12,39H2,(H3,37,38)(H,40,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416939
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccccc1=O)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O2/c30-22-11-10-20(24(12-9-18-7-8-18)37-13-2-1-6-27(37)39)15-23(22)35-28(40)25-16-26(29(31,32)33)36-38(25)21-5-3-4-19(14-21)17-34/h1-6,10-11,13-16,18,24H,7-9,12,17,34H2,(H,35,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439603
PNG
(US10633345, Compound 227d | US10689346, Compound 2...)
Show SMILES NC(=N)c1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H26F4N6O/c30-22-12-11-19(26(36-16-17-9-10-17)18-5-2-1-3-6-18)14-23(22)37-28(40)24-15-25(29(31,32)33)38-39(24)21-8-4-7-20(13-21)27(34)35/h1-8,11-15,17,26,36H,9-10,16H2,(H3,34,35)(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417032
PNG
(1-(1-aminoisoquinolin-7-yl)-N-(5-(3-cyclopropyl-1-...)
Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccc(=O)[nH]c1=O)C(F)(F)F
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416773
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-(((cyclopropylmethy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H27F4N5O/c30-23-12-11-21(27(35-17-18-9-10-18)20-6-2-1-3-7-20)14-24(23)36-28(39)25-15-26(29(31,32)33)37-38(25)22-8-4-5-19(13-22)16-34/h1-8,11-15,18,27,35H,9-10,16-17,34H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416777
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cn[nH]c1)C(F)(F)F
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416790
PNG
(1-(3-(Aminomethyl)phenyl)-N-(2-chloro-5-((cyclopro...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1Cl)C(NCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C28H26ClF3N6O/c29-22-9-8-19(26(35-15-17-6-7-17)20-4-2-10-34-16-20)12-23(22)36-27(39)24-13-25(28(30,31)32)37-38(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,16-17,26,35H,6-7,14-15,33H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416797
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-fluoro-2-methyl-1,2...)
Show SMILES CN1CCc2c(C1)ccc(NC(=O)c1cc(nn1-c1cccc(CN)c1)C(F)(F)F)c2F
Show InChI InChI=1S/C22H21F4N5O/c1-30-8-7-16-14(12-30)5-6-17(20(16)23)28-21(32)18-10-19(22(24,25)26)29-31(18)15-4-2-3-13(9-15)11-27/h2-6,9-10H,7-8,11-12,27H2,1H3,(H,28,32)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439390
PNG
(US10633345, Compound 98b | US10689346, Compound 98...)
Show SMILES FC(F)(F)c1cc(C(=O)Nc2cccc(c2)C(CCC2CC2)N2CCCC2)n(n1)-c1cccc(c1)C#N
Show InChI InChI=1S/C28H28F3N5O/c29-28(30,31)26-17-25(36(34-26)23-8-3-5-20(15-23)18-32)27(37)33-22-7-4-6-21(16-22)24(12-11-19-9-10-19)35-13-1-2-14-35/h3-8,15-17,19,24H,1-2,9-14H2,(H,33,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439400
PNG
(US10633345, Compound 119e | US10689346, Compound 1...)
Show SMILES COc1ccccc1C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H30F3N5O2/c1-40-26-11-3-2-10-24(26)28(35-18-19-12-13-19)21-7-5-8-22(15-21)36-29(39)25-16-27(30(31,32)33)37-38(25)23-9-4-6-20(14-23)17-34/h2-11,14-16,19,28,35H,12-13,17-18,34H2,1H3,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416838
PNG
(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cccc(OC(F)(F)F)c1)C(F)(F)F
Show InChI InChI=1S/C30H27F6N5O2/c31-29(32,33)26-15-25(41(40-26)23-8-1-4-19(12-23)16-37)28(42)39-22-7-2-5-20(13-22)27(38-17-18-10-11-18)21-6-3-9-24(14-21)43-30(34,35)36/h1-9,12-15,18,27,38H,10-11,16-17,37H2,(H,39,42)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416848
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES Cc1cc(C(=O)Nc2cccc(c2)C(NCC2CC2)c2ccccc2)n(n1)-c1cccc(CN)c1
Show InChI InChI=1S/C29H31N5O/c1-20-15-27(34(33-20)26-12-5-7-22(16-26)18-30)29(35)32-25-11-6-10-24(17-25)28(31-19-21-13-14-21)23-8-3-2-4-9-23/h2-12,15-17,21,28,31H,13-14,18-19,30H2,1H3,(H,32,35)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439426
PNG
(US10633345, Compound 108e | US10689346, Compound 1...)
Show SMILES NCc1cccc(c1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C30H31F3N6O/c31-30(32,33)27-15-26(39(38-27)25-9-2-5-21(13-25)17-35)29(40)37-24-8-3-7-23(14-24)28(36-18-19-10-11-19)22-6-1-4-20(12-22)16-34/h1-9,12-15,19,28,36H,10-11,16-18,34-35H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416851
PNG
(1-(3-(Aminomethyl)phenyl)-N-(3-((isopropylamino)(p...)
Show SMILES CC(C)NC(c1ccccc1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C28H28F3N5O/c1-18(2)33-26(20-9-4-3-5-10-20)21-11-7-12-22(15-21)34-27(37)24-16-25(28(29,30)31)35-36(24)23-13-6-8-19(14-23)17-32/h3-16,18,26,33H,17,32H2,1-2H3,(H,34,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416876
PNG
(1-(3-(Aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES COc1cccc(C(NCC2CC2)c2cccc(NC(=O)c3cc(nn3-c3cccc(CN)c3)C(F)(F)F)c2)c1O
Show InChI InChI=1S/C30H30F3N5O3/c1-41-25-10-4-9-23(28(25)39)27(35-17-18-11-12-18)20-6-3-7-21(14-20)36-29(40)24-15-26(30(31,32)33)37-38(24)22-8-2-5-19(13-22)16-34/h2-10,13-15,18,27,35,39H,11-12,16-17,34H2,1H3,(H,36,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416893
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(F)cc1F)C(F)(F)F
Show InChI InChI=1S/C29H26F5N5O/c30-20-9-10-23(24(31)13-20)27(36-16-17-7-8-17)19-4-2-5-21(12-19)37-28(40)25-14-26(29(32,33)34)38-39(25)22-6-1-3-18(11-22)15-35/h1-6,9-14,17,27,36H,7-8,15-16,35H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416896
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(((cyclopropylmethy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1cc(F)ccc1F)C(F)(F)F
Show InChI InChI=1S/C29H26F5N5O/c30-20-9-10-24(31)23(13-20)27(36-16-17-7-8-17)19-4-2-5-21(12-19)37-28(40)25-14-26(29(32,33)34)38-39(25)22-6-1-3-18(11-22)15-35/h1-6,9-14,17,27,36H,7-8,15-16,35H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439471
PNG
(US10633345, Compound 54e | US10633345, Compound 70...)
Show SMILES CN(C(c1cccc(c1)C#N)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1)C1CC1
Show InChI InChI=1S/C30H26F4N6O/c1-39(22-9-10-22)28(20-6-2-4-18(12-20)16-35)21-8-11-24(31)25(14-21)37-29(41)26-15-27(30(32,33)34)38-40(26)23-7-3-5-19(13-23)17-36/h2-8,11-15,22,28H,9-10,17,36H2,1H3,(H,37,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416930
PNG
(1-(3-(Aminomethyl)phenyl)-N-(3-((3-bromo-4-hydroxy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccc(O)c(Br)c1)C(F)(F)F
Show InChI InChI=1S/C29H27BrF3N5O2/c30-23-13-20(9-10-25(23)39)27(35-16-17-7-8-17)19-4-2-5-21(12-19)36-28(40)24-14-26(29(31,32)33)37-38(24)22-6-1-3-18(11-22)15-34/h1-6,9-14,17,27,35,39H,7-8,15-16,34H2,(H,36,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416903
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopro...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C30H28F4N4O2/c31-24-12-11-22(29(40,14-13-19-9-10-19)21-6-2-1-3-7-21)16-25(24)36-28(39)26-17-27(30(32,33)34)37-38(26)23-8-4-5-20(15-23)18-35/h1-8,11-12,15-17,19,40H,9-10,13-14,18,35H2,(H,36,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416942
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccncc1=O)C(F)(F)F
Show InChI InChI=1S/C28H26F4N6O2/c29-21-8-7-19(23(9-6-17-4-5-17)37-11-10-34-16-26(37)39)13-22(21)35-27(40)24-14-25(28(30,31)32)36-38(24)20-3-1-2-18(12-20)15-33/h1-3,7-8,10-14,16-17,23H,4-6,9,15,33H2,(H,35,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416906
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H31F4N5O2/c1-45-29-14-12-22-6-2-3-8-25(22)31(29)32(40-19-20-9-10-20)23-11-13-26(35)27(16-23)41-33(44)28-17-30(34(36,37)38)42-43(28)24-7-4-5-21(15-24)18-39/h2-8,11-17,20,32,40H,9-10,18-19,39H2,1H3,(H,41,44)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416751
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C30H29F3N4O2/c31-30(32,33)27-18-26(37(36-27)25-11-4-6-21(16-25)19-34)28(38)35-24-10-5-9-23(17-24)29(39,15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,16-18,20,39H,12-15,19,34H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416906
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((cyclopropylmethyl...)
Show SMILES COc1ccc2ccccc2c1C(NCC1CC1)c1ccc(F)c(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H31F4N5O2/c1-45-29-14-12-22-6-2-3-8-25(22)31(29)32(40-19-20-9-10-20)23-11-13-26(35)27(16-23)41-33(44)28-17-30(34(36,37)38)42-43(28)24-7-4-5-21(15-24)18-39/h2-8,11-17,20,32,40H,9-10,18-19,39H2,1H3,(H,41,44)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416794
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(5-((cycloprop...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C28H25F4N5O2/c29-22-9-8-19(26(39-16-17-6-7-17)20-4-2-10-34-15-20)12-23(22)35-27(38)24-13-25(28(30,31)32)36-37(24)21-5-1-3-18(11-21)14-33/h1-5,8-13,15,17,26H,6-7,14,16,33H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416900
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((3-cyanophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(OCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C30H25F4N5O2/c31-24-10-9-22(28(41-17-18-7-8-18)21-5-1-3-19(11-21)15-35)13-25(24)37-29(40)26-14-27(30(32,33)34)38-39(26)23-6-2-4-20(12-23)16-36/h1-6,9-14,18,28H,7-8,16-17,36H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416960
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-(3-cyclopropyl-1-(2...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(CCC1CC1)n1ccc(=O)[nH]c1=O)C(F)(F)F
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416837
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((cyclopropylmethyl...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1O)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-15-24(37(36-26)22-8-3-5-19(13-22)16-33)28(39)35-21-7-4-6-20(14-21)27(34-17-18-11-12-18)23-9-1-2-10-25(23)38/h1-10,13-15,18,27,34,38H,11-12,16-17,33H2,(H,35,39)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416981
PNG
((+)-N-(5-(1-amino-3-cyclopropyl-1-(pyridin-3-yl)pr...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccnc1)C(F)(F)F
Show InChI InChI=1S/C29H28F4N6O/c30-23-9-8-20(28(35,11-10-18-6-7-18)21-4-2-12-36-17-21)14-24(23)37-27(40)25-15-26(29(31,32)33)38-39(25)22-5-1-3-19(13-22)16-34/h1-5,8-9,12-15,17-18H,6-7,10-11,16,34-35H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416991
PNG
((+)-N-(3-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(N)(CCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C31H29F3N6O/c32-31(33,34)28-17-27(40(39-28)26-9-2-5-22(15-26)19-36)29(41)38-25-8-3-7-24(16-25)30(37,13-12-20-10-11-20)23-6-1-4-21(14-23)18-35/h1-9,14-17,20H,10-13,19,36-37H2,(H,38,41)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416998
PNG
((+)-N-(5-(1-amino-1-(4-cyanophenyl)-3-cyclopropylp...)
Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1ccc(cc1)C#N)C(F)(F)F
Show InChI InChI=1S/C33H27F4N7O/c34-26-10-8-23(32(40,13-11-19-1-2-19)22-6-3-20(18-38)4-7-22)15-27(26)42-31(45)28-17-29(33(35,36)37)43-44(28)24-9-5-21-12-14-41-30(39)25(21)16-24/h3-10,12,14-17,19H,1-2,11,13,40H2,(H2,39,41)(H,42,45)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM417007
PNG
((+)-N-(5-(1-amino-1-(3-cyanophenyl)-3-cyclopropylp...)
Show SMILES Nc1nccc2ccc(cc12)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(N)(CCC1CC1)c1cccc(c1)C#N)C(F)(F)F
Show InChI InChI=1S/C33H27F4N7O/c34-26-9-7-23(32(40,12-10-19-4-5-19)22-3-1-2-20(14-22)18-38)15-27(26)42-31(45)28-17-29(33(35,36)37)43-44(28)24-8-6-21-11-13-41-30(39)25(21)16-24/h1-3,6-9,11,13-17,19H,4-5,10,12,40H2,(H2,39,41)(H,42,45)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416720
PNG
(1-(3-(aminomethyl)phenyl)-N-(2-fluoro-3-(phenyl(pr...)
Show SMILES CCCN(c1ccccc1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1F
Show InChI InChI=1S/C27H25F4N5O/c1-2-14-35(19-9-4-3-5-10-19)22-13-7-12-21(25(22)28)33-26(37)23-16-24(27(29,30)31)34-36(23)20-11-6-8-18(15-20)17-32/h3-13,15-16H,2,14,17,32H2,1H3,(H,33,37)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416751
PNG
(Racemic 1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopro...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C30H29F3N4O2/c31-30(32,33)27-18-26(37(36-27)25-11-4-6-21(16-25)19-34)28(38)35-24-10-5-9-23(17-24)29(39,15-14-20-12-13-20)22-7-2-1-3-8-22/h1-11,16-18,20,39H,12-15,19,34H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM439347
PNG
(US10633345, Compound 41e | US10689346, Compound 41...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1ccccc1)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O/c30-29(31,32)26-16-25(37(36-26)24-11-4-6-20(14-24)17-33)28(38)35-23-10-5-9-22(15-23)27(34-18-19-12-13-19)21-7-2-1-3-8-21/h1-11,14-16,19,27,34H,12-13,17-18,33H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416767
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-(3-cyclopropyl-1-hy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(O)(CCC1CC1)c1ccccn1)C(F)(F)F
Show InChI InChI=1S/C29H28F3N5O2/c30-29(31,32)26-17-24(37(36-26)23-8-3-5-20(15-23)18-33)27(38)35-22-7-4-6-21(16-22)28(39,13-12-19-10-11-19)25-9-1-2-14-34-25/h1-9,14-17,19,39H,10-13,18,33H2,(H,35,38)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416792
PNG
(1-(3-(aminomethyl)phenyl)-N-(5-((3-aminophenyl)(cy...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cc(ccc1F)C(NCC1CC1)c1cccc(N)c1)C(F)(F)F
Show InChI InChI=1S/C29H28F4N6O/c30-23-10-9-20(27(36-16-17-7-8-17)19-4-2-5-21(35)12-19)13-24(23)37-28(40)25-14-26(29(31,32)33)38-39(25)22-6-1-3-18(11-22)15-34/h1-6,9-14,17,27,36H,7-8,15-16,34-35H2,(H,37,40)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416804
PNG
(2-(3-Aminomethyl-phenyl)-5-trifluoromethyl-2H-pyra...)
Show SMILES COc1ccc2cc(ccc2c1)C(NCC1CC1)c1cccc(NC(=O)c2cc(nn2-c2cccc(CN)c2)C(F)(F)F)c1
Show InChI InChI=1S/C34H32F3N5O2/c1-44-29-13-12-23-15-26(11-10-24(23)17-29)32(39-20-21-8-9-21)25-5-3-6-27(16-25)40-33(43)30-18-31(34(35,36)37)41-42(30)28-7-2-4-22(14-28)19-38/h2-7,10-18,21,32,39H,8-9,19-20,38H2,1H3,(H,40,43)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Plasma kallikrein


(Homo sapiens (Human))
BDBM416813
PNG
(1-(3-(aminomethyl)phenyl)-N-(3-((10-chloroanthrace...)
Show SMILES NCc1cccc(c1)-n1nc(cc1C(=O)Nc1cccc(c1)C(NCC1CC1)c1c2ccccc2c(Cl)c2ccccc12)C(F)(F)F
Show InChI InChI=1S/C37H31ClF3N5O/c38-34-29-13-3-1-11-27(29)33(28-12-2-4-14-30(28)34)35(43-21-22-15-16-22)24-8-6-9-25(18-24)44-36(47)31-19-32(37(39,40)41)45-46(31)26-10-5-7-23(17-26)20-42/h1-14,17-19,22,35,43H,15-16,20-21,42H2,(H,44,47)
PDB

Reactome pathway

UniProtKB/SwissProt

antibodypedia
GoogleScholar
PC cid
PC sid
UniChem
US Patent
25.1n/an/an/an/an/an/an/an/a



BioCryst Pharmaceuticals, Inc.

US Patent


Assay Description
The effect of compounds of the invention on human plasma kallikrein activity was determined using the chromogenic substrates. In these experiments, 2...


US Patent US10689346 (2020)

More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 302 total )  |  Next  |  Last  >>
* indicates data uncertainty>20%